Our FDA approved software has been used daily in the US since 2009. This allowed us to collect and annotate the largest ECG database on the market (>2.5 billion annotated heartbeats).
In 2022 FDA approved next generation DeepRhythm Artificial Intelligence (DRAI) Software Platform. Built on TechBot experience to further reduce the time needed to generate a report while maintaining superior diagnostic yield. The DRAI platform has been built with predictive analytics in mind (presented at ACC).
Our software platform and PocketECG are used to monitor close to 200k patients annually in 22 countries.
We provide software, artificial intelligence, and cloud based solutions to healthcare systems, physicians, and medical technology companies across the globe.
Our commitment to innovation is showcased by our products, such as the latest generation artificial intelligence platform which is FDA approved for cardiac rhythm analysis (DeepRhythmAI), or our AI based CT analysis software for assessment of coronary artery stenosis and coronary vessel plaque analysis.
Building on this vision, our objective is to create a seamless and efficient healthcare system that benefits both medical professionals and patients. We are striving to design AI algorithms that can accurately detect and diagnose diseases at an early stage, saving precious time and increasing the chances of successful treatment. Through the utilization of cloud computing, we aim to facilitate real-time data exchange, enabling doctors to access critical patient information instantly, no matter their geographical location. By enhancing the decision-making process and reducing human errors, we are on a mission to reshape the global healthcare landscape, making it more proactive, personalized, and efficient.
Work with us
Recommend an employee